Home Cart Sign in  
Chemical Structure| 923287-50-7 Chemical Structure| 923287-50-7

Structure of Opicapone
CAS No.: 923287-50-7

Chemical Structure| 923287-50-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Opicapone is a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

Synonyms: BIA 9-1067

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Opicapone

CAS No. :923287-50-7
Formula : C15H10Cl2N4O6
M.W : 413.17
SMILES Code : CC1=[N+]([O-])C(Cl)=C(C2=NOC(C3=CC([N+]([O-])=O)=C(O)C(O)=C3)=N2)C(C)=C1Cl
Synonyms :
BIA 9-1067
MDL No. :MFCD19443745
InChI Key :ASOADIZOVZTJSR-UHFFFAOYSA-N
Pubchem ID :135565903

Safety of Opicapone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Opicapone (BIA 9-1067) serves as a potent third-generation catechol-O-methyltransferase (COMT) inhibitor, primarily utilized in Parkinson's disease and motor fluctuation research. It reduces cellular ATP content with an IC50 of 98 μM[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02092168 Parkinson Disease PHASE1 COMPLETED 2025-01-09 BIOTRIAL, Rueil, Malmaison, F-... More >>92501, France Less <<
NCT01851850 Parkinson Disease PHASE3 COMPLETED 2016-05-24 Rabin Medical Center, Petach T... More >>iqva, Hamerkaz, 49100, Israel Less <<
NCT04787965 Parkinson Disease COMPLETED 2022-08-04 Neurocrine clinical site, Los ... More >>Gatos, California, 95032, United States|Neurocrine clinical site, Memphis, Tennessee, 38157, United States|Neurocrine clinical site, Christiansburg, Virginia, 24073, United States|Neurocrine clinical site, Norfolk, Virginia, 68134, United States|Neurocrine clinical site, Auburn, Washington, 98002, United States|Neurocrine clinical site, Crab Orchard, West Virginia, 25827, United States Less <<
NCT02071823 Parkinson PHASE1 COMPLETED 2025-06-08 Algorithme Pharma Inc., Mount-... More >>Royal, Quebec, H3P 3P1, Canada Less <<
NCT04986995 Parkinson Disease PHASE4 ACTIVE_NOT_RECRUITING 2025-06-23 Hospital da Senhora da Oliveir... More >>a - Guimar?es, E.P.E, Servi?o de Neurologia, Guimar?es, 4835-044, Portugal Less <<
NCT01515891 Parkinson Disease PHASE1 COMPLETED 2025-09-10 Covance Basel Research Unit AG... More >> (formerly Swiss Pharma Contract Ltd), Allschwil, Base, CH-4123, Switzerland Less <<
NCT02101190 Parkinson's Disease PHASE1 COMPLETED 2025-05-10 Biotrial, 7-9 rue Jean-Louis B... More >>ertrand, Rennes, F-35000, France|City clinical Hospital N°64, Moscow, 17292, Russian Federation|City clinical Hospital N°3, Moscow, Russian Federation Less <<
NCT02305329 Epilepsy PHASE1 COMPLETED 2025-04-14 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.42mL

0.48mL

0.24mL

12.10mL

2.42mL

1.21mL

24.20mL

4.84mL

2.42mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories